2024 SABCS|Results Unveiled for the Phase III Study of Disitamab Vedotin in Treating HER2-Positive Advanced Breast Cancer with Liver Metastasis
YANTAI,China,Dec. 13,2024-- On the morning of December 12,2024 (UTC-6),at the Poster Spotlight Session "Novel HER2 Therapeutics" of the 47th San Antonio Breast Cancer Symposium (SABCS),Reme